You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
尖峯集團(600668.SH):恩格列淨獲得化學原料藥上市申請批準通知書

格隆匯7月29日丨尖峯集團(600668.SH)公佈,全資子公司浙江尖峯藥業有限公司收到國家藥品監督管理局關於化學原料藥恩格列淨的《化學原料藥上市申請批準通知書》。恩格列淨是一種鈉-葡萄糖協同轉運蛋白2(SGLT2)抑制劑。與運動和飲食結合,作爲改善II型糖尿病成年患者的血糖控制的輔助治療。恩格列淨能夠阻斷腎臟中葡萄糖的再吸收作用,將過多的葡萄糖排泄到體外,從而達到降低血糖水平的效果,而且該降糖效果不依賴於β細胞功能和胰島素抵抗。截至本公告日,恩格列淨在CDE原輔包登記信息平臺顯示狀態爲“A”的企業共二十八家,爲江蘇豪森藥業集團有限公司、浙江華海藥業股份有限公司等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account